Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The combined analysis of carfilzomib trials for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.18
Views: 987

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Prof Maria-Victoria Mateos speaks to ecancer at the ASH 2018 Annual Meeting about the efficacy and safety results of carfilzomib and dexmethasone in lenalidomide exposed and refractory multiple myeloma patients.

She outlines the rationale for the carfilzomib trials in the relapsed setting mentioning three specific clinical trials: ENDEAVOR, CHAMPION-1 and ARROW.

She then explains the toxicity profile of carfilzomib and concludes that it is something that could be incorporated into everyday practice, with the next step being combining carfilzomib and dexamethasone with a monoclonal antibody.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation